Ying Gu

Prof. Ying Gu


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2021 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
PDF file
CWChen Wang
Chen Wang
JZJiawei Zhang
Jiawei Zhang
JYJie Yin
Jie Yin
YGYichao Gan
Yichao Gan
SXSenlin Xu
Senlin Xu
WHWendong Huang
Wendong Huang
The Myc proto-oncogene family consists of three members, C-MYC, MYCN, and MYCL, which encodes the transcription factor c-Myc (hereafter Myc), N-Myc, and L-Myc, respectively. Myc protein orchestrates diverse physiological processes, including cell proliferation, differentiation, survival, and apoptosis. Myc modulates about 15% of the global transcriptome, and its deregulation rewires the cellular signaling modules inside tumor cells, thereby acquiring selective advantages. The deregulation of Myc occurs in >70% of human cancers, and is related to poor prognosis; hence, hyperactivated Myc oncoprotein has been proposed as an ideal drug target for decades. Nevertheless, no specific drug is currently available to directly target Myc, mainly because of its “undruggable” properties: lack of enzymatic pocket for conventional small molecules to bind; inaccessibility for antibody due to the predominant nucleus localization of Myc. Although the topic of targeting Myc has actively been reviewed in the past decades, exciting new progresses in this field keep emerging. In this review, after a comprehensive summarization of valuable sources for potential druggable targets of Myc-driven cancer, we also peer into the promising future of utilizing macropinocytosis to deliver peptides like Omomyc or antibody agents to intracellular compartment for cancer treatment.

20 May 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
JZJiawei Zhang
Jiawei Zhang
YGYichao Gan
Yichao Gan
HLHongzhi Li
Hongzhi Li
JYJie Yin
Jie Yin
XHXin He
Xin He
WHWendong Huang
Wendong Huang
Cyclin-dependent kinase 2 (CDK2) complex is significantly over-activated in many cancers. While it makes CDK2 an attractive target for cancer therapy, most inhibitors against CDK2 are ATP competitors that are either nonspecific or highly toxic, and typically fail clinical trials. One alternative approach is to develop non-ATP competitive inhibitors; they disrupt interactions between CDK2 and either its partners or substrates, resulting in specific inhibition of CDK2 activities. In this report, we identify two potential druggable pockets located in the protein-protein interaction interface (PPI) between CDK2 and Cyclin A. To target the potential druggable pockets, we perform a LIVS in silico screening of a library containing 1925 FDA approved drugs. Using this approach, homoharringtonine (HHT) shows high affinity to the PPI and strongly disrupts the interaction between CDK2 and cyclins. Further, we demonstrate that HHT induces autophagic degradation of the CDK2 protein via tripartite motif 21 (Trim21) in cancer cells, which is confirmed in a leukemia mouse model and in human primary leukemia cells. These results thus identify an autophagic degradation mechanism of CDK2 protein and provide a potential avenue towards treating CDK2-dependent cancers.

30 June 2023 in Leukemia
Verified
Journal Article
Closed access
PDF file
JJJie Jiang
Jie Jiang
JCJiangqing Chen
Jiangqing Chen
CLChan Liao
Chan Liao
YDYanting Duan
Yanting Duan
YWYajie Wang
Yajie Wang
JSJie Sun
Jie Sun

4 October 2023 in Experimental Hematology & Oncology
Verified
Journal Article
Open access
PDF file
YYYiyi Yao
Yiyi Yao
XLXiangjie Lin
Xiangjie Lin
CWChen Wang
Chen Wang
YGYing Gu
Ying Gu
JJJie Jin
Jie Jin
HWHuafeng Wang
Huafeng Wang
Nucleophosmin (NPM1) is a widely expressed nucleocytoplasmic shuttling protein with prominent nucleolar localization. It is estimated that 25–35% of adult patients with acute myeloid leukemia (AML) carryNPM1mutations. The classicNPM1type A mutation occurs in exon 12, which accounts for 75–80% of adult patients withNPM1-mutated AML. It produces an additional leucine and valine-rich nuclear export signal (NES) at the C-terminus, and causes aberrant cytoplasmic dislocation of NPM1 protein. Notably, emerging evidence indicates that besides the classic type A mutation, rare mutants occurring in other exons may also lead to the imbalance of the nucleocytoplasmic shuttle of NPM1. Identification of novel non-type A mutants is crucial for the diagnosis, prognosis, risk stratification and disease monitoring of potential target populations. Here we reported a novelNPM1mutation in exon 5 identified from a de novo AML patient. Similar to the classic type A mutation, the exon 5 mutation had the NPM1 mutant bound to exportin-1 and directed the mutant into the cytoplasm by generating an additional NES sequence, resulting in aberrant cytoplasmic dislocation of NPM1 protein, which could be reversed by exportin-1 inhibitor leptomycin B. Our findings strongly support that besides the exon 12 mutation, the exon 5 mutant is anotherNPM1“born to be exported” mutant critical for leukemogenesis. Therefore, similar to the classic type A mutation, the identification of our novelNPM1mutation is beneficial for clinical laboratory diagnosis, genetic risk assessment and MRD monitoring.

4 March 2021 in Frontiers of Medicine
Verified
Journal Article
Closed access
PDF file
CWChen Wang
Chen Wang
HFHui Fang
Hui Fang
JZJiawei Zhang
Jiawei Zhang
YGYing Gu
Ying Gu

1 November 2019 in Experimental Cell Research
Verified
Journal Article
Closed access
QYQingfeng Yu
Qingfeng Yu
YXYing Xu
Ying Xu
HZHaifeng Zhuang
Haifeng Zhuang
ZWZhaoxing Wu
Zhaoxing Wu
LZLei Zhang
Lei Zhang
RXRongzhen Xu
Rongzhen Xu